COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
Article
[키워드] adjusted
age
All participant
anti-SARS-CoV-2
anti-TNF
antibody
Antibody binding
antibody concentration
Antibody concentrations
approved
available data
boost
booster
case-control study
combination therapy
Concentration
control group
COVID-19
COVID-19 vaccine
Diagnosis
disease
dose
Evidence
first dose
geometric mean
geometric mean ratio
group
groups
had no
healthy control
healthy individuals
heterologous vaccine
homologous
IBD
Immunosuppressed
immunosuppressed patient
immunosuppressive
Immunosuppressive treatment
Infection
Inflammatory bowel disease
jak inhibitors
multicentre
multivariable
nine
no significant difference
Older
Older age
participant
Patient
patients treated
Pfizer
Primary outcome
receiving
Receptor binding domain
recipient
recruited
reduced
regimen
response
S1 RBD
SARS-COV-2 infection
SARS-CoV-2 spike
SARS-CoV-2 vaccination
significantly
significantly lower
Support
T-cell Response
T-cell responses
the healthy
therapy
Tofacitinib
Treatment
ulcerative colitis
Vaccine
vaccine dose
vaccine doses
vaccine-induced antibody response
VIP
were measured
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
[DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기